2min chapter

Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

CHAPTER

Telebressive: The Evolutionary Food Chain in the Sector

We're very positive into some really great top line results, benefit on spleen volume, benefit on symptom score, low toxicity addition to jackify alone. That is a telebressive being better than their competitor. But we also think that there's a lot of strategic optionality. Once you've got a de-risked asset that everybody says it's synergistic with the standard of care and it leads to a lot better patient outcomes, that's going to be very valuable. And so if they showed good top line results in December, then you're talking about from then end of year 24 when they're getting approved.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode